|1.||Mishra, Ram K: 6 articles (04/2015 - 12/2005)|
|2.||Johnson, Rodney L: 5 articles (04/2015 - 12/2005)|
|3.||Basu, Dipannita: 4 articles (04/2015 - 01/2011)|
|4.||Hui, Patricia: 2 articles (04/2015 - 01/2013)|
|5.||Bhandari, Jayant: 2 articles (04/2015 - 01/2013)|
|6.||Tian, Yuxin: 2 articles (04/2015 - 01/2013)|
|7.||Tan, Mattea L: 1 article (04/2013)|
|8.||Kwiecien, Jacek M: 1 article (04/2013)|
|9.||Daya, Ritesh P: 1 article (03/2013)|
|10.||Beyaert, Michael G R: 1 article (03/2013)|
|1.||Schizophrenia (Dementia Praecox)
04/01/2013 - "Findings from this study demonstrate a better safety profile of PAOPA, and necessitates the progression of this newly developed therapeutic for the treatment of schizophrenia."
01/01/2013 - "It improves our understanding on the diverse mechanisms of action of allosteric modulators, while advancing PAOPA's development into a novel drug for the improved treatment of schizophrenia."
04/01/2013 - "Previous studies have shown PAOPA to attenuate schizophrenia-like behavioral abnormalities in preclinical models. "
04/01/2015 - "We have previously shown that PAOPA, by selectively modulating D2R, can ameliorate schizophrenia-like symptoms in animal models, although the precise mechanism is presently not understood. "
03/01/2013 - "Of these compounds, PAOPA is among the most potent allosteric modulators, and has been shown to be effective in treating the MK-801 induced preclinical animal model of schizophrenia. "
12/01/2005 - "The present study was undertaken to investigate the role of the hypothalamic tripeptide L-prolyl-L-leucyl-glycinamide (PLG) and its conformationally constrained analog 3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) in modulating agonist binding to human dopamine (DA) receptor subtypes using human neuroblastoma SH-SY5Y cells stably transfected with respective cDNAs. "
|3.||Movement Disorders (Movement Disorder)
|2.||Dizocilpine Maleate (Dizocilpine)
|4.||Synapsins (Synapsin I)
|7.||Dopamine D2 Receptors (Dopamine D2 Receptor)
|10.||MSH Release-Inhibiting Hormone (MIF-I)